Chugai Pharmaceutical (OTCMKTS:CHGCY) Issues Quarterly Earnings Results

Key Points

• Chugai Pharmaceutical reported quarterly earnings of $0.20 EPS and generated $2.01 billion in revenue.
• The company boasts a return on equity of 21.35% and a net margin of 33.08%.
• CHGCY stock is currently priced at $24.71 with a market capitalization of $81.32 billion.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.20 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $2.01 billion for the quarter. Chugai Pharmaceutical had a return on equity of 21.35% and a net margin of 33.08%.

Chugai Pharmaceutical Trading Up 2.3%

CHGCY stock opened at $24.71 on Friday. The stock has a market capitalization of $81.32 billion, a PE ratio of 31.28 and a beta of 0.66. Chugai Pharmaceutical has a 12-month low of $19.51 and a 12-month high of $31.26. The stock's 50 day simple moving average is $25.17 and its 200 day simple moving average is $24.48.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.